England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, Kwikpen, was endorsed in January by the Medicines & Healthcare products Regulatory Agency (MHRA). The product was cleared for both type 2 diabetes and obesity patients.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.